Here are three things to know.
1. XLH, which causes low phosphorous levels in the blood, leads to impaired bone growth in children and issues with bone mineralization in adults.
2. In a recent clinical trial, a majority of patients (94 percent) demonstrated normal phosphorus levels after taking Crysvita once a month, compared to just 8 percent of patients taking a placebo.
“XLH differs from other forms of rickets in that vitamin D therapy is not effective,” said Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. “This is the first FDA-approved medication for the treatment of XLH and a real breakthrough for those living with this serious disease.”
3. The FDA granted both a breakthrough therapy designation and an orphan drug designation for Crysvita.
More articles on supply chain:
‘Convoluted’ and ‘expensive’ among US employers’ most common descriptors for the drug supply chain
Mylan eliminates more than 400 positions at West Virginia plant: 3 notes
Safety violations at PharMEDium worsen hospital painkiller shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
